It occurs in approximately 20, 12, and 5% of patients with stageII, III, and IV CRC, respectively.68 In stage II–III CRC, dMMR/MSI-H strongly correlates with an improvedprognosis compared with MMR proficient/microsatellite stable (pMMR/MSS) tumorsand is a predictor for lack of benefit from fluoropyrimidine monotherapy instage II patients.69,70 Conversely, dMMR/MSI-H appears to be associated withworse prognosis in patients with mCRC.71, , , –75 This finding may berelated to the enrichment of BRAF V600 mutations in patientswith sporadic dMMR/MSI mCRC.74,76. The gene discussed is BRAF; the disease is colorectal carcinoma.